Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Table 2 GFR in SCD patients on hydroxyurea therapy and not on hydroxyurea therapy

Sr.no	Authors	N	Mean age (years)	GFR entry	On hydroxyurea (months)	GFR exit	Hydroxyurea dose (mg/kg/day)
Sr.no	Authors	N	Mean age (years)	Mean (SD)	On hydroxyurea (months)	Mean (SD)	Hydroxyurea dose (mg/kg/day)
1	Alvarez O et al. 2012	193	1.15	126.42 (38.8)^b	24	146.64 (43·7)	20
2	Thornburg CD et al. 2009	14	2·.91	139.2 (19.5)^b	24	144.3 (15.69)	28
3	Aygun B et al. 2013	23	7.4	167 (46)^a	25	145 (27)	24.4
4	Hankins JS et al. 2014	8	17.1	140.7 (17.5)	72	117.7 (22.5)	26.6
5	Silva Junior GB et al. 2014	26	32.1	105 (30)^a	NA	112 (21)	1000 g^c
6	Bartolucci P et al. 2015	58	35	124.5 (33.3)^a	6	120.5 (2.83)	15 mg
7	Laurin LP et al. 2014	70	37	151 (55)^a	73	128 (58)	1207 mg^c

ISSN: 2046-4053